Loading...
Thumbnail Image
Publication

Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics

Chen, Jennifer C. J.
King, Oliver D.
Zhang, Yuanfan
Clayton, Nicholas P.
Spencer, Carrie
Wentworth, Bruce M.
Emerson, Charles P. Jr.
Wagner, Kathryn R.
Embargo Expiration Date
Link to Full Text
Abstract

Derepression of DUX4 in skeletal muscle has emerged as a likely cause of pathology in facioscapulohumeral muscular dystrophy (FSHD). Here we report on the use of antisense phosphorodiamidate morpholino oligonucleotides to suppress DUX4 expression and function in FSHD myotubes and xenografts. The most effective was phosphorodiamidate morpholino oligonucleotide FM10, which targets the polyadenylation signal of DUX4. FM10 had no significant cell toxicity, and RNA-seq analyses of FSHD and control myotubes revealed that FM10 down-regulated many transcriptional targets of DUX4, without overt off-target effects. Electroporation of FM10 into FSHD patient muscle xenografts in mice also down-regulated DUX4 and DUX4 targets. These findings demonstrate the potential of antisense phosphorodiamidate morpholino oligonucleotides as an FSHD therapeutic option.

Source

Mol Ther. 2016 Aug;24(8):1405-11. doi: 10.1038/mt.2016.111. Epub 2016 Jun 3. Link to article on publisher's site.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1038/mt.2016.111
PubMed ID
27378237
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.